# The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine

> **NCT03294135** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 194 (actual)

## Conditions studied

- Virus Diseases

## Interventions

- **BIOLOGICAL:** Encepur Adults

## Key facts

- **NCT ID:** NCT03294135
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-05
- **Primary completion:** 2021-10-25
- **Final completion:** 2021-10-25
- **Target enrollment:** 194 (ACTUAL)
- **Last updated:** 2024-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03294135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03294135, "The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03294135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*